AbbVie has recently licensed rights to a monoclonal antibody discovered by Argenx, ARGX-115, paying $20MM up-front and up to $625MM in milestones based on development, approval, and commercial performance. This monoclonal antibody targets a central player in the complex tumor microenvironment – the regulatory T-cell (Treg).
What is the Tumor Microenvironment?
The nature of the tumor microenvironment is critical for therapy of cancer. An inflammatory phenotype is critical for the development and maintenance of an effective anti-cancer immune response. Even if CD8+ T-cells traffic into the tumor microenvironment, their effect can be abrogated by various checkpoints [CTLA-4, PD-(L)1, TIM-3, LAG-3, and CD73], and suppressive immune cells and molecules including MDSC’s (myeloid-derived suppressor cells), Treg cells, TGF-β, nitric oxide, and IDO (indoleamine-2,3-dioxygenase).
What is GARP?
GARP (glycoprotein A repetitions predominant) is a:
Type 1 transmembrane protein with 20 leucine-rich repeats in the extracellular domain, a single transmembrane domain, and a short 14-amino acid cytoplasmic tail. GARP is highly expressed by platelets, activated regulatory T cells (Tregs), mesenchymal stromal cells, hepatic stellate cells, and transformed tumor cells.
Multiple studies have established that GARP plays a role in activating TGF-β by mediating the surface expression and integrin-mediated activation of latent TGF. GARP associates with latency-associated peptide to form an alternative cell-surface platform for latent TGF-β presentation. GARP participates in the regulatory function of activated Tregs, demonstrated by impaired suppressive activity upon GARP silencing and inefficient support by GARP KO T cells for the generation of inducible Tregs. Aberrant overexpression of GARP in the tumor microenvironment also promotes Treg generation and immune escape.
GARP is responsible for TGF-β release by Treg cells in the tumor microenvironment. TGF-β is a potent pro-cancer cytokine:
- induces the trans-differentiation of T-cells into Treg cells,
- blocks proliferation of T-helper and CD8+ T-cells, and
- prevents maturation of – and MHC Class II presentation by dendritic cells
- Induces cancer cells to express PDGF-receptor, leads to autocrine loop of PDGF proliferation
- Induces release of MMP-9, which causes breakdown of stroma for the invading cancer
Monoclonal Antibodies to GARP
Monoclonal antibodies to a specific region on GARP have shown to block TGF-β secretion by Treg cells:
Two anti-GARP monoclonal antibodies were generated that block the production of active TGF-b1 by human Tregs. These antibodies recognize a conformational epitope that requires amino acids GARP137–139 within GARP/TGF-b1 complexes. A variety of antibodies recognizing other GARP epitopes did not block active TGF-b1 production by Tregs. In a model of xenogeneic graft-versus-host disease in NSG mice, the blocking antibodies inhibited the immunosuppressive activity of human Tregs. These antibodies may serve as therapeutic tools to boost immune responses to infection or cancer via a mechanism of action distinct from that of currently available immunomodulatory antibodies. Used alone or in combination with tumor vaccines or antibodies targeting the CTLA4 or PD1/PD-L1 pathways, blocking anti-GARP antibodies may improve the efficiency of cancer immunotherapy.
The goal, then, is to turn cold tumors hot by blocking TGF-β release by Treg cells. This will allow trafficking of CD8+ T-cells and dendritic cells into the tumor microenvirnoment that will precipitate and maintain an adaptive antigen-specific immune response. Then, anti-PD(L)1 monoclonal antibodies will block the abrogating effect of PD-L1 expression by tumor cells, which will allow for more complete immune-mediate killing and eradication of tumors.
Argnx generated anti-GARP antibodies using it SIMPLE antibody platform, which leverages the immune system of outbred llamas to generate antibodies against human antigen targets.